Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis

NCT00442650 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.

NCT NCT00442650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00442650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis
Lead sponsor
Merck KGaA, Darmstadt, Germany
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2004
Completion date
December 31, 2005
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe psoriasis